Penumbra Company Leadership
| PEN Stock | USD 230.38 0.28 0.12% |
Penumbra employs about 4.5 K people. The company is managed by 26 executives with a total tenure of roughly 103 years, averaging almost 3.0 years of service per executive, having 173.08 employees per reported executive. Analysis of Penumbra's management performance can provide insight into the firm performance.
| Adam Elsesser Chairman Chairman of the Board, Chief Executive Officer |
| James Pray President President International |
Penumbra Management Team Effectiveness
The company has Return on Asset of 0.0582 % which means that on every $100 spent on assets, it made $0.0582 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.035 %, implying that it generated $0.035 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities.Penumbra Workforce Comparison
Penumbra is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 15,541. Penumbra totals roughly 4,500 in number of employees claiming about 29% of equities under Health Care industry.
The company has Net Profit Margin of 0.03 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.12 %, which entails that for every 100 dollars of revenue, it generated $0.12 of operating income. Penumbra Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Penumbra insiders, such as employees or executives, is commonly permitted as long as it does not rely on Penumbra's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Penumbra insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adam Elsesser over three weeks ago Disposition of 195 shares by Adam Elsesser of Penumbra at 257.12 subject to Rule 16b-3 | ||
Adam Elsesser over a month ago Disposition of 172 shares by Adam Elsesser of Penumbra at 255.73 subject to Rule 16b-3 | ||
Adam Elsesser over a month ago Disposition of 229 shares by Adam Elsesser of Penumbra at 273.4 subject to Rule 16b-3 | ||
Adam Elsesser over a month ago Disposition of 260000 shares by Adam Elsesser of Penumbra subject to Rule 16b-3 | ||
Adam Elsesser over two months ago Disposition of 1105 shares by Adam Elsesser of Penumbra at 276.47 subject to Rule 16b-3 | ||
Maggie Yuen over two months ago Disposition of 900 shares by Maggie Yuen of Penumbra at 158.3 subject to Rule 16b-3 | ||
Harpreet Grewal over three months ago Disposition of 200 shares by Harpreet Grewal of Penumbra at 267.17 subject to Rule 16b-3 | ||
Maggie Yuen over three months ago Disposition of 250 shares by Maggie Yuen of Penumbra at 283.25 subject to Rule 16b-3 |
Penumbra Notable Stakeholders
A Penumbra stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Penumbra often face trade-offs trying to please all of them. Penumbra's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Penumbra's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Adam Elsesser | Chairman of the Board, Chief Executive Officer | Profile | |
| Adam JD | Chairman, CoFounder | Profile | |
| James Pray | President International | Profile | |
| Gita Barry | President Healthcare | Profile | |
| Lynn Rothman | Executive Vice President, Chief Business Officer | Profile | |
| Johanna Roberts | Executive Vice President General Counsel, Secretary | Profile | |
| Sandra Lesenfants | President Interventional | Profile | |
| Maggie Yuen | Chief Financial Officer | Profile | |
| Surbhi Sarna | Independent Director | Profile | |
| Bridget ORourke | Independent Director | Profile | |
| Holly Sit | Director Development | Profile | |
| Harpreet Grewal | Independent Director | Profile | |
| Don Kassing | Presiding Independent Director | Profile | |
| Thomas Wilder | Independent Director | Profile | |
| Arani Bose | Executive Director and Chief Innovator | Profile | |
| Janet Leeds | Lead Independent Director | Profile | |
| Johanna JD | General VP | Profile | |
| Ben Tompkins | Executive Development | Profile | |
| Shruthi Narayan | Executive Interventional | Profile | |
| Arani MD | CoFounder Director | Profile | |
| Pankaj Tiwari | Executive Officer | Profile | |
| Jee HamlynHarris | Investor Officer | Profile | |
| Ben Sorci | Executive Operations | Profile | |
| Lambert Shiu | Chief Accounting Officer | Profile | |
| MD FSIR | Chief Officer | Profile | |
| Jason Mills | Executive Strategy | Profile |
About Penumbra Management Performance
The success or failure of an entity such as Penumbra often depends on how effective the management is. Penumbra management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Penumbra management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Penumbra management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. Penumbra operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 3800 people.
Penumbra Workforce Analysis
Traditionally, organizations such as Penumbra use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Penumbra within its industry.Penumbra Manpower Efficiency
Return on Penumbra Manpower
| Revenue Per Employee | 265.5K | |
| Revenue Per Executive | 45.9M | |
| Net Income Per Employee | 3.1K | |
| Net Income Per Executive | 538.9K | |
| Working Capital Per Employee | 176.2K | |
| Working Capital Per Executive | 30.5M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Penumbra. If investors know Penumbra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Penumbra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Penumbra is measured differently than its book value, which is the value of Penumbra that is recorded on the company's balance sheet. Investors also form their own opinion of Penumbra's value that differs from its market value or its book value, called intrinsic value, which is Penumbra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Penumbra's market value can be influenced by many factors that don't directly affect Penumbra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Penumbra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Penumbra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Penumbra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.